AEON Biopharma, Inc. Form 8-K Summary
Business Context and Reporting Period
AEON Biopharma, Inc. filed a Form 8-K dated July 24, 2023, under Item 7.01, Regulation FD Disclosure. The filing states that company representatives intended to make presentations at investor conferences and other forums. The filing does not report results for a specific fiscal quarter or year.
The company was formerly named Priveterra Acquisition Corp. Its Class A common stock and warrants trade on the New York Stock Exchange under the symbols AEON and AEON WS, respectively.
Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, balance-sheet data, or other quantitative financial metrics.
Material Changes Versus Prior Comparable Period
No period-to-period financial or operating comparison is provided. The principal disclosure is the planned use of an investor presentation dated July 2023.
Guidance, Outlook, Risks, and Unusual Items
- The investor presentation may contain information disclosed to investors, analysts, and other parties, including updates or modifications.
- The presentation is furnished under Regulation FD and is not deemed filed for purposes of Section 18 of the Exchange Act, except where specifically incorporated by reference.
- The company states that the presentation should be considered together with its other SEC filings and public announcements.
- The company undertakes no obligation to update or revise the presentation, although it may do so through subsequent SEC filings, press releases, or other disclosures.
- The filing text provided does not include the substantive contents of Exhibit 99.1; therefore, no specific guidance, clinical, commercial, financial, or risk disclosures from the presentation can be summarized.
Key Facts for Investors to Verify
- Review Exhibit 99.1, the July 2023 investor presentation, for the underlying business, product, clinical, regulatory, financial, and strategic information.
- Confirm any statements in the presentation against the company’s subsequent SEC filings and public announcements.
- Verify that information in the presentation is furnished rather than filed and assess the implications for reliance and incorporation by reference.
- Review later filings for updates to management’s outlook, liquidity, financing needs, clinical development plans, and material risks.